Rocket Pharmaceuticals
RCKT
66 hedge funds and large institutions have $147M invested in Rocket Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 11 closing their positions.
1,800% more call options, than puts
Call options by funds: $19K | Put options by funds: $1K
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
14% more funds holding
Funds holding: 58 → 66 (+8)
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
4% more capital invested
Capital invested by funds: $141M → $147M (+$5.78M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
Top Sellers
RCKT Hedge Fund Activity: Q2 2016 in Review
66 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2016, worth a combined $147M — up 4.1% from $141M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RCKT positions and 11 closed out — a net gain of 8 holders — while 18 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $3.77M. The largest seller was Tekla Capital Management, cutting an estimated $2.7M.
- 66 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2016, up from 58 in Q1 2016.
- Funds reported $147M of Rocket Pharmaceuticals stock for Q2 2016, up 4.1% quarter-over-quarter.
- 19 funds opened new Rocket Pharmaceuticals positions in Q2 2016 and 11 closed out, a net change of +8 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $3.77M added.
- The largest Rocket Pharmaceuticals seller in Q2 2016 was Tekla Capital Management, an estimated $2.7M sold.
Based on aggregated 13F filings for Q2 2016.